Futura Medical Share Discussion Threads

[harryhayes] 13/3/2023 12:30

What is your motivation LBO?

You are coming across like a child having a tantrum having dropped there ice cream.

Educated investors do their own research and don't to take notice of seemingly insane rantings.

Why not go elsewhere and troll a few babies so the grown up can converse in peace

[lbo] 13/3/2023 10:41

Yes I agree it is ‘very sad!’ indeed! Especially when its now 2023 and its openly being admitted its going to be ‘long term’ to try build a brand around just placebo medical device gel made with alcohol, water, glycol and carbomer ingredients with no enforceable patent


JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774
FUTURA a winner for 2015 - says it all!


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775
What's another year after all?
At FUM, time is measured in decades.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders.




Here's a startling fact: between 80% and 90% of new product launches fail, according to multiple studies including Harvard Business Review. Each year, more than 30,000 new products hit the market, from companies large and small, and year after year, history is littered with dead carcasses



Research at the Ehrenberg-Bass Institute shows new product launches can be a risky undertaking for brand owners. Investigating 83,719 new product introductions over an eight-year period, the research finds around one in four new products failed to survive one year after launch. This failure rate increased to around 40% two years after launch.



Why Most Product Launches Fail

[lbo] 12/3/2023 22:52

The following conditions have demonstrated positive responses to the placebo effect:

Pain (so FLEXISEQ a sham placebo gel ‘works’ just like any placebo drug free gel ‘works’

Erectile dysfunction (so Eroxon a sham placebo gel ‘works just like any placebo drug free gel ‘works’)


People with erectile dysfunction responded well to placebo treatment.

In one study, participants were split into three groups. The first group was told they would receive a treatment for erectile dysfunction, the second group was told they would receive either a placebo or an actual treatment, and the third group was told they would receive a placebo.

All three groups were, in fact, given placebo starch tablets, but the erectile dysfunction in all three groups improved significantly without any differences between the three groups.



After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction



The Placebo Effect: How Important Is It in ED Treatment?



Experience has shown that while oral analgesic trials elicit some placebo response among subjects, placebo response rates tend to increase with transdermal gel

Thus, the placebo effect has become increasingly frustrating as drug companies seek to take advantage of the popularity and established safety of transdermal delivery systems.





One specialist commentator felt that the clinical effectiveness has not been demonstrated. The absence of an adequate placebo (an inactive topical gel) for highlighted as a limitation by 3 commentators. One commentator said that without it, the clinical effectiveness could be attributed to the placebo effect of rubbing a gel'

[lbo] 12/3/2023 22:42

The FTC will be asking for Eroxon to substantiate its claims because the studies on which the company relies on do not show its any more effective then a placebo gel or even an arousal gel



Administrative Law Judge Upholds FTC's Complaint that POM Deceptively Advertised Its Products erectile dysfunction claims were false and unsubstantiated because the study on which the company relied did not show that POM Juice was any more effective than a placebo.



The Erection of a Placebo
When yesterday's placebo is tomorrow's treatment

So how effective is MED3000 really?

The first thing to note is that MED3000 has never been shown to be more effective than any control treatment - because it was the control treatment.

[petroc] 12/3/2023 22:35

The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.

[petroc] 12/3/2023 21:41

The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.

[lbo] 12/3/2023 21:25

So where did Futura get the ‘IDEA’ to market the placebo MED3000 gel after MED2005 gel (Dermasys & GTN) failed its Phase 3 trial?

Look no further then Futuras TPR100 (dermasys & Diclofenac). Yes the pain product gel in manufacturing scale up limbo with Thornton & Ross since 2017.

One of Futuras transdermal delivery competitors according to Edison (see link) was working on IDEA-033 (transfersome gel & Ketoprofen). J&J had the the rights to IDEA-033 before they walked away as it too like Med2005 failed its phase 3 drug trail.

Which then left Pro Bono Bio (PBB) with just the sham placebo Flexiseq (Transfersome gel on its own often referred to as TDT064 in the scientific literature). You couldn’t make it up if you tried.

And coincidentally Glaxo also walked away from Futuras TPR100 as well as the MED product. They learned all they needed to know about Dermasys is just a placebo and walked away.

[petroc] 12/3/2023 21:18

The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.

LiarBO recycles the same posts over and over again, and therefore gets the same answers each time. 'Insanity is doing the same thing over and over and expecting different results.'

[petroc] 12/3/2023 21:17

'The Petroc multi-ID bot must be broken and seems to be stuck repeating the same post!'

Oh, the irony!

[petroc] 12/3/2023 21:01

"Rusnano invests hundreds of million dollars in placebo 'nano-gel'. Clinical tests of Flexiseq ointment have not proved its effectiveness. The drug was to be distributed by a friend of a Rusnano senior executive"
Another day another scam in Russia...
en.crimerussia.com/corruption/rus…

hxxps://staging.threadreaderapp.com/thread/980229644547915776.html

[lbo] 12/3/2023 20:46

Yes like the irony of you saying Flexiseq is a ‘Russian scam’. Which by your definition means Eroxon is a English AIM market scam! LOL





Flexiseq was a certified Class IIb medical device. We understood that the device certification was granted by a body within the European Member States that had been designated to carry out conformity assessments under the Medical Device Directive.


I wonder how much money and ‘work hard to build Eroxon™ into a long term, profitable and trusted brand’ will be required when it still has no enforceable patent!?



The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered




‘Futura does not have the marketing or regulatory resources to support the day-to-day requirements in a growing compliance-driven medical device market’

˜the immediate potential for substantial royalties is low in the absence of a large global brand 'carrier' to take the product forward’

[petroc] 12/3/2023 19:29

The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.

LiarBO recycles the same posts over and over again, and therefore gets the same answers each time. 'Insanity is doing the same thing over and over and expecting different results.'

[petroc] 12/3/2023 19:28

'The Petroc multi-ID bot must be broken and seems to be stuck repeating the same post!'

Oh, the irony!

[lbo] 12/3/2023 19:15

And the rampers are aware of all this from the failed TPR100 product stuck in limbo! Its even already been openlyadmitted the Dermasy vehicle and Voltaren vehicle gave similar results! LOLhttps://indigo.bluematrix.com/indigo/Viewer.action?info=U7Z%2F%2BSxWYbPQB8QtqH%2Bh5KgushbvU5dK'TPR100 gave similar results to the gold standard, Voltarol 2% gel'https://www.gskhealthpartner.com/content/dam/cf-consumer-healthcare/health-professionals/en_IN/pdf/article-1.pdfThe cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moisturizing properties and fragrance.https://www.edisoninvestmentresearch.com/?ACT=18&ID=10479A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect